Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Measles paradox: how a virus both wipes and boosts immune memory

NCT ID NCT06923631

Knowledge-focused Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 100 children to understand why measles causes short-term immune suppression but also lifelong immunity. Researchers will measure antibodies and immune cells before and after infection to see how measles changes the body's immune memory. The goal is to solve the 'measles paradox' and improve future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Children in group A will be from 4 up to and including 17 years of age and include children who are not protected against measles. Families willing to participate will self-identify them to the researchers, with the help of schools, Municipal Health Services and regional general practitioners. Children in group B will be from 4 up to and including 17 years of age and have received one or two MMR vaccinations, depending on their age. The children will be recruited from the same geographical regions with low vaccine coverage as the children in group A, for example classmates.

Ages

4 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group A * Aged 4 - 17 years old * Susceptible to measles * No pre-existing immunity against measles (vaccination or earlier infection) Group B * Aged 4 - 17 years old * Protected against measles due to vaccination or earlier infection Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * Diagnosed chronic disease that lasted over 3 months * Immune suppression (due to medication or underlying disease) * Group A; Detectable MeV-antibodies in the T1 blood sample

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Measles disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

measles

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Measles disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ErasmusMC

    Rotterdam, South Holland, 3015GD, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.